肝内胆管癌新辅助治疗的热点与进展

Hotspots and advances in neoadjuvant therapy for intrahepatic cholangiocarcinoma

肝内胆管癌是起源于肝内二级及以上胆管分支上皮细胞的恶性肿瘤,其发病率在全世界范围内呈明显上升趋势,由于其发病隐匿,早期临床症状不典型,侵袭性强,确诊时常处于进展期,预后较差,根治性手术是延长患者生存期的唯一治疗方法,但术后极易发生复发和转移,5年生存率低。新辅助治疗是指在手术前给予药物治疗或其他治疗方式,以减小肿瘤的大小、降低复发风险、提高手术切除的成功率或为手术提供更佳的局部控制。目前尚无标准化的新辅助治疗方案,其对预后的潜在作用也存在争议。本文就肝内胆管癌新辅助治疗的热点与进展进行综述。

Intrahepatic cholangiocarcinoma(ICC)is a malignant tumor that originates from the epithelial cells of the intrahepatic bile ducts,specifically the secondary and higher branches.The incidence rate of ICC tends to increase significantly worldwide.Due to its insidious onset,atypical clinical symptoms in the early stage,and strong invasiveness,it is often in the advanced stage at the time of diagnosis,which may result in poor prognosis.Radical surgery is the only treatment method to prolong the survival time of patients,but recurrence and metastasis frequently occur after surgery,leading to a low 5-year survival rate.Neoadjuvant therapy refers to the administration of drug treatment or other treatment modalities before surgery to reduce tumor size,lower the risk of recurrence,increase the success rate of surgical resection,or provide better local control for surgery.Currently,there is still no standardized regimens for neoadjuvant therapy,and its potential impact on prognosis remains controversial.This article reviews the hotspots and advances in neoadjuvant therapy for ICC.